Appointments

Roemmler-Zehrer brings with her a strong track record of experience in clinical and medical affairs, with specific experience in drug development and leadership roles at pharmaceutical companies such as Celgene, Amgen and Ipsen. She has been involved in several successful product development programmes including Celgene’s Abraxane for pancreatic cancer and non-small cell lung cancer and Ipsen’s Cabometyx in renal cell carcinoma and thyroid cancer. She has also led teams spanning various disciplines in multiple therapeutic areas including oncology, inflammation, rheumatology, dermatology, neurology and rare diseases.

Gertjan Bartlema, chief executive officer of Immodulon, stated: “I am delighted to welcome incoming Josefine to the new leadership team at Immodulon as we prepare to advance our lead asset IMM-101 into a pivotal trial. Josefine brings a wealth of global experience in clinical and medical affairs from leading pharmaceutical companies and will be instrumental in our efforts to unlock the full potential of IMM-101. We look forward to benefiting from Josefine’s insights and leadership as we finalise the design of our pivotal trial in pancreatic cancer and advance our mission to improve the lives of patients suffering from this difficult-to-treat cancer.”

Commenting on her appointment, Roemmler-Zehrer added: “I am so pleased to be joining Immodulon at this pivotal time in the company’s development. I have been excited and inspired by the new management’s energy and commitment to bring IMM-101, a new, transformative, broad-spectrum immunotherapy to patients with pancreatic cancer. Pancreatic cancer has the highest mortality of any solid tumour and patients have few meaningful treatment options. I believe that IMM-101 can make a major contribution in addressing this fatal disease.”